Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBITDA (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBITDA for 9 consecutive years, with -$12.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 46.31% to -$12.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.3 million, a 92.3% increase, with the full-year FY2025 number at -$5.3 million, up 92.3% from a year prior.
  • EBITDA was -$12.2 million for Q4 2025 at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $29.4 million in Q2 2022 to a low of -$83.0 million in Q2 2021.
  • A 5-year average of -$25.2 million and a median of -$15.3 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 135.46% in 2022, then crashed 1389.82% in 2024.
  • Akebia Therapeutics' EBITDA stood at -$69.9 million in 2021, then skyrocketed by 86.81% to -$9.2 million in 2022, then surged by 119.18% to $1.8 million in 2023, then plummeted by 1389.82% to -$22.8 million in 2024, then skyrocketed by 46.31% to -$12.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBITDA are -$12.2 million (Q4 2025), $540000.0 (Q3 2025), and $247000.0 (Q2 2025).